Vera Kolatzki

High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation

Kai Wille, Parvis Sadjadian, Tatjana Becker et al. · Annals of Hematology · 2018 · 32 citations · Full text

Medicine, Hematology, Oncology +16

Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms

Karlo Huenerbein, Parvis Sadjadian, Tatjana Becker et al. · Annals of Hematology · 2020 · 28 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Rohit Sekhri, Parvis Sadjadian, Tatjana Becker et al. · Annals of Hematology · 2021 · 22 citations · Full text

Medicine, Hematology, Oncology +10

Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN

Frank Stegelmann, Kai Wille, Hannah Busen et al. · Leukemia · 2020 · 16 citations · Full text

Medicine, Hematology, Oncology +16

Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety

Lukas Schrickel, Florian H. Heidel, Parvis Sadjadian et al. · Journal of Cancer Research and Clinical Oncology · 2020 · 13 citations · Full text

Medicine, Hematology, Obstetrics +7